Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Conavi Medical ( (TSE:CNVI) ) has shared an update.
Conavi Medical Corp. has announced a proposed public offering of units to raise funds for the development and pre-clinical testing of its Novasight 3.0 technology, aiming for a 510(k) clearance application to the U.S. FDA by August 2025. This offering, led by Bloom Burton Securities Inc., will also support working capital and general corporate purposes, positioning Conavi to strengthen its operations and market presence in the cardiovascular imaging sector.
More about Conavi Medical
Conavi Medical is a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures. The company is known for its Novasight Hybrid System, which uniquely combines intravascular ultrasound and optical coherence tomography to provide comprehensive imaging of coronary arteries. The system has received regulatory approvals in the U.S., Canada, China, and Japan.
YTD Price Performance: 17.73%
Average Trading Volume: 5,487
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.97M
For an in-depth examination of CNVI stock, go to TipRanks’ Stock Analysis page.